|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.690 HKD | +2.24% |
|
+1.28% | +3.08% |
| 05/08 | CSPC Pharma Gets $10 Million Milestone Payment from AstraZeneca Under Research Deal | MT |
| 05/08 | CSPC Pharma, AstraZeneca Form JV to Build Biologics Manufacturing Facility in China | MT |
Company Valuation: CSPC Pharmaceutical Group Limited
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,00,932 | 97,707 | 86,022 | 55,169 | 96,380 | 99,353 | - | - |
| Change | - | -3.19% | -11.96% | -35.87% | 74.7% | 3.08% | - | - |
| Enterprise Value (EV) 1 | 89,633 | 86,241 | 72,284 | 46,931 | 86,710 | 88,638 | 85,515 | 81,933 |
| Change | - | -3.79% | -16.18% | -35.07% | 84.76% | 2.22% | -3.52% | -4.19% |
| P/E | 14.7x | 14.1x | 13.5x | 12.1x | 21.8x | 12.1x | 14.1x | 12.9x |
| PBR | 3.17x | 2.86x | 2.39x | 1.62x | 2.56x | 2.31x | 2.11x | 1.92x |
| PEG | - | 14.13x | -1.73x | -0.5x | -9.88x | 0.1x | -1x | 1.46x |
| Capitalization / Revenue | 2.94x | 2.77x | 2.52x | 1.78x | 3.26x | 2.78x | 2.82x | 2.65x |
| EV / Revenue | 2.61x | 2.44x | 2.12x | 1.51x | 2.94x | 2.48x | 2.43x | 2.18x |
| EV / EBITDA | 9.5x | 9.43x | 8.39x | 6.22x | 12.1x | 6.93x | 8.61x | 7.78x |
| EV / EBIT | 10.7x | 10.8x | 9.77x | 7.68x | 15.6x | 9.6x | 11.1x | 10x |
| EV / FCF | 23.7x | 14.1x | 26.2x | 17.5x | 19.5x | 12x | 12.3x | 8.74x |
| FCF Yield | 4.22% | 7.11% | 3.82% | 5.71% | 5.12% | 8.31% | 8.16% | 11.4% |
| Dividend per Share 2 | 0.18 | 0.21 | 0.28 | 0.26 | 0.29 | 0.3699 | 0.3697 | 0.3847 |
| Rate of return | 2.13% | 2.56% | 3.86% | 5.44% | 3.44% | 4.26% | 4.25% | 4.43% |
| EPS 2 | 0.5773 | 0.5831 | 0.5376 | 0.3946 | 0.3859 | 0.7189 | 0.6181 | 0.6728 |
| Distribution rate | 31.2% | 36% | 52.1% | 65.9% | 75.2% | 51.5% | 59.8% | 57.2% |
| Net sales 1 | 34,309 | 35,292 | 34,175 | 31,046 | 29,533 | 35,696 | 35,175 | 37,540 |
| EBITDA 1 | 9,431 | 9,148 | 8,615 | 7,547 | 7,168 | 12,782 | 9,929 | 10,529 |
| EBIT 1 | 8,366 | 7,952 | 7,400 | 6,113 | 5,564 | 9,230 | 7,705 | 8,187 |
| Net income 1 | 6,901 | 6,949 | 6,382 | 4,632 | 4,409 | 7,935 | 6,932 | 7,548 |
| Net Debt 1 | -11,298 | -11,467 | -13,738 | -8,238 | -9,670 | -10,715 | -13,838 | -17,420 |
| Reference price 2 | 8.470 | 8.200 | 7.260 | 4.780 | 8.430 | 8.690 | 8.690 | 8.690 |
| Nbr of stocks (in thousands) | 1,19,16,370 | 1,19,15,520 | 1,18,48,756 | 1,15,41,665 | 1,14,33,025 | 1,14,33,025 | - | - |
| Announcement Date | 22/03/22 | 22/03/23 | 20/03/24 | 28/03/25 | 25/03/26 | - | - | - |
1HKD in Million2HKD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 12.09x | 2.48x | 6.93x | 4.26% | 1.27TCr | ||
| 33.6x | 12.3x | 24.81x | 0.58% | 1,05700Cr | ||
| 28.84x | - | - | 2.07% | 62TCr | ||
| 32.43x | 7.35x | 15.3x | 2.81% | 43TCr | ||
| 20.47x | 4.85x | 12.02x | 2.72% | 36TCr | ||
| 22.14x | 5.72x | 14.28x | 2.8% | 30TCr | ||
| 20.58x | 4.25x | 12.07x | 2.07% | 25TCr | ||
| 25.76x | 6.78x | 12.06x | 2.45% | 22TCr | ||
| 13.84x | 4.97x | 10.44x | 3.68% | 21TCr | ||
| -41.37x | 5.93x | 33.46x | 2.47% | 17TCr | ||
| Average | 16.84x | 6.07x | 15.71x | 2.59% | 36.33TCr | |
| Weighted average by Cap. | 24.41x | 8.07x | 18.26x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 1093 Stock
- Valuation CSPC Pharmaceutical Group Limited
Select your edition
All financial news and data tailored to specific country editions
















